预约演示
更新于：2025-11-04
Doxofylline
多索茶碱
更新于：2025-11-04
概要
基本信息
原研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C11H14N4O4 |
InChIKeyHWXIGFIVGWUZAO-UHFFFAOYSA-N |
CAS号69975-86-6 |
关联
34
项与 多索茶碱 相关的临床试验CTR20251480
多索茶碱片在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验。
CTR20244717
多索茶碱片在中国健康受试者中空腹给药条件下药代动力学比对研究
CTR20243176
多索茶碱片在健康受试者中空腹状态下的单剂量、随机、开放、四周期、完全重复交叉设计的生物等效性试验
100 项与 多索茶碱 相关的临床结果
登录后查看更多信息
100 项与 多索茶碱 相关的转化医学
登录后查看更多信息
100 项与 多索茶碱 相关的专利（医药）
登录后查看更多信息
237
项与 多索茶碱 相关的文献（医药）2025-07-03Bioanalysis
A validated method for the determination of doxofylline and its pharmacokinetic application in healthy volunteers
Article
作者: Liu, Danrui ; Luo, Kaiwei ; Hu, Yu ; Dai, Menglong ; Zhang, Huina ; Zhao, Hangyu ; Yu, Yonghua
BACKGROUND:
Current HPLC-based methods for doxofylline analysis lack speed and precision. A rapid, specific, and sensitive UPLC-MS/MS method was developed for the determination of doxofylline in this study.
RESEARCH DESIGN AND METHODS:
This method was fully validated and doxophylline-d4 was used as an internal standard. A Kinetex-C18 column (EVO 100Å, 50 × 2.1 mm, 5 μm) was used for the separation procedure, with mobile phases consisting of 0.3% formic acid (A) and 90% acetonitrile solution with 0.3% formic acid (B). The total runtime of the gradient elution procedure was 2.6 minutes. The mass spectrometry analysis was carried out employing a multiple reaction monitoring model and using the transitions of m/z 267.000→181.000 for doxofylline and m/z 271.200→181.100 for the internal standard.
RESULTS:
The linear range of detection for doxophylline was between 20.0 to 16,000 ng/mL. The intra-batch accuracy deviations of each concentration level ranged from -8.0% to 2.5%, while the intra-batch precisions ranged from 1.3% to 9.0%. And the inter-batch accuracy deviations were -5.8% ~0.8%, while the inter-batch precisions were 2.2% ~7.0%.
CONCLUSIONS:
This method was applied to pharmacokinetic clinical trials of single oral administration of doxophylline tablets successfully.
CLINICAL TRIAL REGISTRATION:
www.clinicaltrials.gov identifier is CTR20240006 and CTR20233665.
2025-06-17ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Photoelectrochemical Iron(III) Catalysis for Late‐Stage C─H Fluoroalkylations
Article
作者: Trienes, Sven ; Oliveira, João C. A. ; Stückl, Claudia ; Motornov, Vladimir ; Ackermann, Lutz ; Resta, Simonetta ; von Münchow, Tristan ; Lin, Zhipeng ; Liu, Zhi
Abstract:
Chemo‐ and site‐selective functionalization of complex molecules poses a fundamental challenge. Herein, we introduce a resource‐economic photoelectrocatalysis strategy to enable versatile direct fluoroalkylations catalyzed by Earth‐abundant iron and paired with the hydrogen evolution reaction (HER). Notably, the devised approach proved amenable to versatile late‐stage C─H fluoroalkylations of bio‐relevant heterocycles, such as xanthines, nucleobases, and nucleosides. Mechanistic studies supported a ligand‐to‐metal charge transfer‐induced formation of the fluoroalkyl radical.
2025-05-16MEDICINE
A non-toxigenic Corynebacterium diphtheriae biovar Belfanti isolated from a patient with rheumatoid arthritis in China: Insights from a comprehensive genome-based analysis
Article
作者: Na, Wanlin ; Sun, Wei ; Liu, Yuan ; Liu, Ming ; Xie, Huajie ; Jia, Qin ; Liu, Youde ; Wang, Yanyan ; Chang, Kai
Rationale::
Diphtheria is caused by infection with Corynebacterium diphtheriae and is typically associated with upper respiratory tract involvement, which can manifest with high invasiveness. However, in recent years, non-toxigenic C diphtheriae strains have increasingly emerged as major pathogens responsible for invasive diseases. The uniqueness of this case lies in the challenges of culturing and identifying the bacterial strain, its atypical upper respiratory tract manifestations (which are easily overlooked clinically), and its potential for covert transmission, all of which warrant heightened clinical attention.
Patient concerns::
A 71-year-old female patient with rheumatoid arthritis presented to the respiratory department of cough with shortness of breath for >2 months.
Diagnoses::
Pulmonary infections caused by Proteus vulgaris and C diphtheriae biovar Belfanti, and pulmonary interstitial fibrosis.
Interventions::
The patient received intravenous infusion of cefoperazone sodium and sulbactam sodium. Concurrently, doxofylline was prescribed. The patient continued to receive aerosol inhalation of Budesonide Suspension for Inhalation and levosalbutamol hydrochloride.
Outcomes::
The patient had improved chest tightness and shortness of breath, no other special discomfort, and stable vital signs after physical examination.
Lessons::
C diphtheriae biovar Belfanti strain was isolated. The strain can’t decompose nitrate, no virulence gene and drug-resistance gene, but it has strong transposing ability and infection ability, and has the possibility of transforming into a pathogenic strain, which needs to be concerned.
100 项与 多索茶碱 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管炎 | 意大利 | 2001-12-10 | |
| 哮喘 | 意大利 | - | 1988-10-01 |
| 慢性支气管炎 | 意大利 | - | 1988-10-01 |
| 慢性阻塞性肺疾病 | 意大利 | - | 1988-10-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 支气管扩张 | 临床前 | 美国 | - |
登录后查看更多信息
临床结果
临床结果
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用